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of Idiopathic
Pulmonary Fibrosis
Stefania Cerri, MD, PhD, Paolo Spagnolo, MD, PhD,
Fabrizio Luppi, MD, PhD, Luca Richeldi, MD, PhD*
Idiopathic pulmonary fibrosis (IPF) represents one
of the most challenging diseases for chest physi-
cians. The diagnostic process is complex and
requires close interaction with different specialists.
The prognosis of IPF is invariably poor. Notwith-
standing the many treatments used in clinical
practice and evaluated in the context of controlled
randomized trials, the modalities for the follow-up
of patients with IPF are poorly defined. Given the
lack of proof for most interventions, all decisions
need to be extensively discussed and agreed
upon with the patient and their families. As
a consequence, few respiratory disorders require
of chest physicians more interactive skills and
more dedication than IPF.
PHARMACOLOGIC TREATMENTS
The pharmacologic approach to IPF management
has changed as the understanding of the patho-
genesis of the disease has evolved over the last
decade. The initial thinkingwas in favor of a disease
triggered by a persistent inflammatory process, re-
sulting in the induction of fibrosis and scarring of
the lungs. As such, several trials were performed
evaluating the efficacy of drugs that primarily exert
their functions by suppressing inflammatory or
immune responses (such as corticosteroids and
nonsteroid immunomodulatory agents). Current
treatment approaches favor agents with antifibrotic
properties. A systematic assessment of the
evidence available for different therapeutic options
in IPF has been recently published as an evidence-
based guideline.1 A summary of the therapeutic
recommendations listed in this important docu-
ment, formulated according to the Grades of
Recommendation Assessment, Development and
Evaluation methodology,2 along with the reported
voting results from the committee members, is
provided in Table 1.
Anti-Inflammatory and Immunomodulatory
Drugs
Patients with IPF have been (and most still
continue to be) treated in many parts of the world
with corticosteroids. A summary of the results
available for the efficacy of corticosteroid in IPF
was first published in 2003 as a Cochrane system-
atic review,3 when no high-quality studies were
identified and only nonrandomized, retrospective,
studies were available. Hence, there was a major
lack of evidence supporting the use of corticoste-
roids in the treatment of IPF. An update of that
same systematic review, published in 2010,4 did
not identify any new additional randomized clinical
trial on the use of steroids in IPF, thus confirming
the persisting lack of evidence for their use in the
management of IPF. This issue has been also reas-
sessed in the current evidence-based guidelines,1
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in which a strong recommendation against the use
of corticosteroid monotherapy in IPF has been
made. This important recommendation relies on
the availability of very-low-quality evidence and
places a high value on preventing treatment-
related morbidity using long-term corticosteroid
therapy. From the aforementioned results, steroids
alone should never be used to treat IPF.
Low-quality evidence is also available for the
use of nonsteroid immunomodulatory drugs
in IPF, such as colchicine, cyclosporin A, cyclo-
phosphamide, or azathioprine, either alone or in
combinationwith corticosteroids5; as such, current
guidelines1 strongly recommend against the use of
immunomodulatory agents in the treatment of
patients with IPF. A weak recommendation against
the use of a combination therapy with azathioprine,
prednisone, and the antioxidant drug N-acetylcys-
teine has also been made.1 Regarding this combi-
nation regimen only one randomized clinical trial
is available, which evaluated the effect ofN-acetyl-
cysteine in patients already receiving combination
therapy with prednisone and azathioprine.6 The
main points of criticism regarding the results of
Table 1
Summary of current evidence-based recommendations on management of patients with IPF
Recommendation
Number of Votes (As in Ref.1)For Against
Strong Weak Weak Strong For Against Abstention Absent
Pharmacologic Therapies in Stable IPF
Corticosteroids alone  0 21 2 8
Colchicine  0 21 2 8
Cyclosporin A  0 21 2 8
Cyclophosphamide 1
corticosteroids
 0 21 2 8
Azathioprine 1
corticosteroids
 0 21 2 8
Prednisone 1 NAC 1
azathioprine
 3 17 3 8
NAC alone  5 15 3 8
Interferon gamma-1b  0 17 6 8
Bosentan  0 10 13 8
Etanercept  0 18 4 9
Anticoagulation therapy  1 20 2 8
Pirfenidone  4 10 17 0
Pharmacologic Therapies in Acute Exacerbations of IPF
Corticosteroids  14 5 1 11
Treatment of comorbidities
Pulmonary hypertension  8 14 1 8
Gastroesophageal reflux  15 8 0 8
Nonpharmacologic Therapies
Long-term oxygen therapy (in
case of resting hypoxemia)
 18 0 4 9
Rehabilitation  19 0 3 9
Mechanical ventilation  2 19 2 8
Lung Transplantation
(Selected Patients)
 21 0 1 9
Official recommendations are not available for sildenafil and imatinib because evidence on these drugs was published
after the publication of the ATS/ERS/JRS/ALAT 2011 guideline document.1 See text for details.
Abbreviations: NA, not applicable; NAC, N-acetylcysteine.
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this trial are related to the substantial drop-out rate
observed in the study (and the consequent statis-
tical corrections needed) and to the lack of a true
(ie, not taking any potentially effective drug)
placebo group. Nonetheless, significant results
supporting the use of the so-called triple therapy
were observed in the change of vital capacity and
diffusing capacity at 12months; however, no differ-
ence was observed in mortality or in other
secondary outcomes, such as dyspnea or quality-
of-life scores. To further investigate the possible
efficacy of N-acetylcysteine in the treatment of
patients with IPF, a three-arm large trial sponsored
by the IPFnet consortium (the PANTHER [Predni-
sone, Azathioprine, and N-acetylcysteine: A Study
That Evaluates Response in IPF] trial) is currently
recruiting patients in the United States. However,
an interim results from this study showed that
compared to placebo, those assigned to triple
therapy had greater mortality, more hospitaliza-
tions, and more serious adverse events, while not
showing any difference in lung function test
changes. Therefore the National Heart, Lung, and
Blood Institute (NHLBI) has recently stopped the
triple-therapy arm of this study (NIH Release on
October 21, 2011). The other two study arms of
this IPF trial comparingNACalone to placebo alone
will continue. At present, N-acetylcysteine, neither
alone nor in combination with prednisone and
azathioprine, can be recommended for the routine
treatment of IPF.
Antifibrotic and Antiproliferative Drugs
Over the last decade, the perspective on IPF path-
ogenesis has profoundly changed.7 The cause of
the disease has not been identified and the patho-
genesis remains largely unknown. Recent findings
suggest that the disease is likely the result of an
aberrant reparative mechanism, following an injury
that primarily targets the lung epithelium. There-
fore, the disease appears to be characterized
by the proliferation and accumulation of fibro-
blasts/myofibroblasts in the lungs, with excessive
deposition of extracellular matrix, resulting in the
fibrotic distortion of the lung architecture, typically
observed by radiologists and pathologists in the
lungs of patients with IPF. Several pathways of
these processes are under investigation at
present, aimed at identifying the key molecular
mediators and the potential sources of myofibro-
blasts as well as the mechanisms responsible for
the initial injury.
As such, recent randomized clinical trials on the
treatment of IPF have shifted their attention to
drugs with antifibrotic and antiproliferative effects.
As a general observation, the rationale for using
most of the drugs tested so far in clinical trials
has been limited because of both the lack of a reli-
able animal model of the disease8 and the relative
scarcity of in vivo and ex vivo data. As a conse-
quence, in some cases the background for con-
ducting clinical trials is derived from post hoc
analyses of previous studies, with the unavoidable
risks related to no predefined statistical analyses
on subgroups.9
Interferon gamma-1b has been one of the
first agents evaluated in IPF for its antifibrotic as
well as immunomodulatory properties. A first small
pilot study10 published in 1999 pioneered the era of
the randomized controlled trial (RCT) in IPF,
showing an unexpected and substantial improve-
ment of lung function in the active treatment group,
which prompted 2 subsequent large randomized,
placebo-controlled clinical trials addressing the
efficacy of this intervention.11,12 Despite the prom-
ising initial results, both trials failed to meet the
primary end points, and a recent meta-analysis on
the efficacy of interferon gamma-1b failed to show
any effect of this treatment on clinically relevant
outcomes, such as overall survival, progression-
free survival, or lung function.5 Therefore, current
guidelines include a strong recommendation
against the use of interferon gamma-1b in the treat-
ment of patients with IPF, based on high-quality
evidence.1 As a consequence, andnotwithstanding
the publication of small uncontrolled studies
suggesting some effect in a minority of patients
with IPF,13,14 interferon gamma-1b is no longer
a therapeutic option for patients with IPF.
Drugs already approved for other indications in
different diseases, but with background for being
effective in fibrotic disorders, have been evaluated
in IPF clinical trials. Coming from the field of pulmo-
nary hypertension (PH), the endothelin receptor A
and B antagonist bosentan has been evaluated in
2 randomized placebo-controlled clinical trials.
The IPF guidelines strongly recommend against
the use of this drug in IPF based on the results of
the first phase II trial,15 which did not reach statis-
tical significance in the primary outcome and only
showed a positive trend toward a benefit for the
drug in some secondary end points. Moreover,
the results of the largest trial on bosentan in IPF16
confirmed the lack of effect of this drug. More
recently, a phase III, randomized, double-blind,
placebo-controlled, multicenter study comparing
ambrisentan (another endothelin receptor antago-
nist selective for type A receptor) to placebo in
subjects with IPF (the ARTEMIS-IPF [Randomized,
Placebo-Controlled Study to Evaluate Safety and
Effectiveness of Ambrisentan in IPF] trial) was
prematurely stopped after an interim analysis
showed no efficacy of the study drug. Furthermore,
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a phase II trial evaluating efficacy and safety in
patients with IPF of another endothelin receptor
antagonist, macitentan, is active, but not recruiting
patients.
Etanercept, an anti–tumor necrosis factor a drug
widely used in rheumatology, has also been evalu-
ated in IPF. A strong recommendation against its
use in IPF has been made in the current guide-
lines.1 In a single, well-conducted, randomized
placebo-controlled trial,17 this drug failed to show
a statistically significant difference between treat-
ment groups, although some effects on secondary
outcomes were noted.
Several novel oncological agents have been tried
in patients with IPF. Imatinib mesylate, a specific
tyrosine kinase inhibitor with activity against Bcr-
Abl, platelet-derived growth factor (PDGF) recep-
tors, and c-kit, has also been studied in IPF. The
inhibitory activity on PDGF receptors suggested
a potential activity in IPF, through the suppression
of the profibrotic and proliferative pathways
mediated by PDGF. However, a recently published
randomized clinical trial on imatinib in patients with
IPF18 failed to demonstrate an effect of this drug
compared with placebo on any of the outcomes
selected for this study, and in particular did not
show a statistically significant difference between
the treatment and the control group in progression-
free survival or in the change of lung function over
time. Also, a multiple kinase inhibitor (BIBF 1120)
has been evaluated in a phase II trial in patients
with IPF.19 The encouraging results of this study20
prompted the initiation of 2 parallel phase III studies,
currently ongoing and aimed at demonstrating the
efficacy of this drug in IPF.
Very low-quality evidence is available for the
usage of anticoagulation therapy in IPF. In fact,
only one small, unblinded, RCT performed in
Japan has been published, showing a survival
benefit in patients receiving anticoagulation, the
effect being attributed to a reduced mortality
during hospitalization for acute exacerbation or
disease progression.21 A larger trial on the efficacy
of the use of anticoagulation therapy in IPF (the
ACE-IPF [Anticoagulant Effectiveness in Idiopathic
Pulmonary Fibrosis] trial), sponsored by the IPFnet
network in the United States, was recently stopped
based on a lack of efficacy at interim analysis.
Pirfenidone is a small synthetic nonpeptide
molecule that has antifibrotic, anti-inflammatory,
and antioxidant properties, with the ability to inter-
fere with transforming growth factor b–induced
collagen synthesis. Promising results from an
open-label phase II study supported the use of
this drug in the treatment of IPF.22 Subsequently,
the results of 2 multicenter trials performed in
Japan and 2 large international multicenter clinical
trials, all randomized and placebo-controlled, as-
sessing the efficacy of pirfenidone compared
with placebo in patients with IPF, have been pub-
lished.23–25 All these trials have been found to have
a sufficient methodological quality, allowing their
inclusion in a recent Cochrane systematic review.5
Based on the results of this meta-analysis, pirfeni-
done appears to reduce the risk of disease
progression (as measured by progression-free
survival) by 30% and to provide a beneficial effect
on the change of lung function from baseline, in
comparison with placebo. Some limitations to
the interpretation of these data still apply, mostly
related to a certain degree of methodological
heterogeneity across studies, mainly regarding
the methodologies for reporting lung-function
results. Current IPF guidelines, considering the
cost of therapy and the potentially relevant side
effects (such as gastrointestinal adverse events,
liver laboratory abnormalities, photosensitivity,
and rash), expressed a weak recommendation
against the use of this drug. However, the majority
of panel experts abstained from this voting. On the
one hand, the Food and Drug Administration has
denied approval for the use of the drug in the
United States, requesting additional data. Conse-
quently, a new study (the ASCEND [Assessment
of Pirfenidone to Confirm Efficacy and Safety in
IPF] trial), comparing pirfenidone and placebo in
patients with IPF, is currently enrolling patients in
North America, Central America, South America,
Australia, and New Zealand. On the other hand,
pirfenidone is approved and commercially avail-
able for the treatment of patients with IPF in India
and Japan; in Europe the drug has been recog-
nized as an orphan drug, and the European
Medicines Agency has approved its use in the
European Community for the treatment of patients
with mild to moderate IPF. Part of these discrep-
ancies can be explained by the fact that the trials
assessing the efficacy of pirfenidone have been
designed with lung function as the primary end
point, whereas in a disease like IPF the reduction
of mortality should be seen as the main goal of
treatment. Although there is increasing evidence
that a change (in particular a 10% decrease) in
forced vital capacity is predictive of subsequent
mortality,26–28 lung function should be seen at
best as a surrogate of mortality. In any case, pirfe-
nidone will enter the European market over the
next months and a named-patient program is
currently ongoing. The administration of pirfeni-
done to all patients with IPF is still a matter of
debate. Patients willing to receive pirfenidone
should be fully informed on the available evidence
for the efficacy of the drug and on the possible side
effects.
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MANAGEMENT OF COMORBIDITIES
IPF is often associated with morbidities (eg, PH
and gastroesophageal reflux) and symptoms (eg,
dyspnea, exercise limitation, fatigue, anxiety,
mood disturbance, sleep disorders) that dramati-
cally affect patients’ lives.
PH affects most patients with IPF at the time of
initial diagnosis, andultimatelymanyof themduring
the course of the disease.29 Patients with IPF with
concomitant PH (defined as a mean pulmonary
artery pressure >25mmHg on right heart catheter-
ization) have more dyspnea, greater impairment of
their exercise capacity, and increased 1-year
mortality in comparison with their counterparts
without PH.30 Once PH has been diagnosed, it is
essential to exclude any causative or contributory
comorbidity, such as obstructive sleep apnea,
congestive heart failure, and pulmonary emboli; in
addition, hypoxia should be sought and treated.
Whether targeting of PH with medications
approved for the treatment of pulmonary arterial
hypertension has any utility in IPF remains unclear.
In a small open-label trial, sildenafil, an oral
phosphodiesterase-5 inhibitor, improved 6-minute
walk distance (6MWD) and pulmonary hemody-
namics without increasing shunt flow or worse-
ning oxygenation.31 However, a subsequent large
multicenter, randomized, double-blind, placebo-
controlled study did notmeet the primary end point
(change of 20% in 6MWD at 12 weeks), although
statistically significant differences favoring silden-
afil were observed in dyspnea, partial pressure of
oxygen, diffusing capacity of lung for carbon mon-
oxide, and quality of life.32
Bosentan, a dual endothelin receptor A and B
antagonist, has been tested in a phase II RCT,15
though in patients not evaluated for the presence
of PH and thus more as an antifibrotic drug.
Although the primary end point (change from base-
line up to month 12 in exercise capacity, as
measured by a modified 6MWD test) was not
reached, the results of a post hoc analysis sug-
gested that bosentan had a beneficial effect on
time to disease progression or death and quality
of life in patients who underwent surgical lung
biopsy,33 thus leading to a larger phase III study,
which failed to demonstrate that bosentan delays
IPF worsening or death, the primary end point.16
As already mentioned, a phase III randomized,
double-blind,placebo-controlled,multicenter study
comparing ambrisentan (an endothelin receptor
antagonist selective for type A receptor) with
placebo in subjectswith IPF (with orwithout associ-
ated PH) has been prematurely stopped after an
interim analysis showing no efficacy of the study
drug. Notwithstanding the disappointing results
from these studies, it is common practice for chest
physicians and cardiologists to observe how the
presence of PH affects patients’ functional status
and portends a worse outcome. Despite limited
evidence of efficacy, current guidelines weakly
recommend a trial of vasomodulatory agents in
patients with moderate to severe PH, as docu-
mented by right heart catheterization (ie, mean
pulmonary artery pressure >35 mm Hg).1
Acid gastroesophageal reflux (GER) is highly
prevalent in patients with IPF, up to one-half of
whom are asymptomatic.34 Experimental animal
studies and descriptive studies in humans suggest
that chronic microaspiration caused by GER may
cause subclinical injury leading to pulmonary
fibrosis.35,36 While the pathobiological significance
of GER in IPF remains to be elucidated, there is
evidence that treatment of GER, either medical or
surgical, may stabilize lung function.37,38 More
recently, Lee and colleagues39 reported in a large
cohort of patients with IPF that use of GERmedica-
tion, (ie, suppression of gastric content acidity with
either proton-pump inhibitors (PPI) or H2 blockers)
was associated with lower high-resolution com-
puted tomography (HRCT) fibrosis score and
longer survival. These authors observed an addi-
tional survival benefit to Nissen fundoplication,
a surgical intervention that reduces not only acid
but alsoweakly acidic reflux and potential microas-
piration, which may also contribute to the develop-
ment of lung fibrosis.40 At present, it is unclear
whether aggressive treatment of GER disease
may improve or halt disease progression. In addi-
tion, PPI only affect the acidity of the refluxate with-
out preventing reflux or microaspiration of gastric
contents. Furthermore, the use of PPI has been
associated with an increased risk of hip fracture
andcommunity-acquiredpneumonia.41,42 Lifestyle
modifications (small meals, raising the head of the
bed) seem reasonable measures to suggest for
symptomatic patients.
MANAGEMENT OF ACUTE EXACERBATION
OF IPF
The clinical course of IPF is usually chronic and
slowly progressive, although somepatients experi-
ence rapidly progressive disease.1 Acute wors-
ening may occur as a consequence of multiple
distinct causes, including respiratory infections,
pulmonary embolism, pneumothorax, and heart
failure; sometimes worsening cannot be linked to
any identifiable cause, and this latter case
is referred to as acute exacerbation of IPF (AE-
IPF)43 (seearticle elsewhere in this issue). Theprog-
nosis of AE-IPF is almost invariably poor; mortality
during hospitalization is as high as 65% and those
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who survive have a greater than 90%mortality rate
in the 6 months following discharge.44
If AE-IPF is suspected, the management should
include chest HRCT, echocardiogram, bronchoal-
veolar lavage, and infection screen to rule out
known and potentially treatable causes of disease
progression. Many patients with AE-IPF require
intensive care, particularly when respiratory failure
is associated with hemodynamic instability, signif-
icant comorbidities, or severe hypoxemia requiring
monitoring of arterial blood gases or mechanical
ventilation.
A systematic review has been performed
summarizing the current knowledge of acute exac-
erbations in IPF, including their treatment.45 Treat-
ment strategies varied in the different studies, but
in almost all of them patients were administered
broad-spectrum antibiotics and pulse doses of
methylprednisolone (0.5–1 g/d) while the previous
dose of oral steroids was also increased; in some
studies, additional immunosuppressionwith cyclo-
phosphamide and cyclosporine was used.
Two small studies showed that use of cyclo-
sporine after treatment with pulse steroids
can increase survival times.46,47 Horita and col-
leagues48 observed a higher survival ratio and
longer survival duration in patients with AE-IPF
treated with a combination therapy of tacrolimus
and methylprednisolone pulse therapy. In the
double-blind, prospective, placebo-controlled, ran-
domized clinical trial by Azuma and colleagues23
evaluating the effect of pirfenidone in patients with
IPF, although statistical significance was not re-
ached for the primary end point (ie, the change
from baseline of the lowest oxygen saturation as
measured by pulse oximetry during the 6-minute
steady-state exercise test), the investigators ob-
served a significant treatment effect on rates of
AE-IPF, which occurred exclusively in the placebo
group. As such, the study was then prematurely
stopped on ethical grounds. Pirfenidone appeared
also to favorably affect time to acute exacerbation
and IPF-relateddeath in the recentCAPACITY [Clin-
ical Studies Assessing Pirfenidone in IPF: Research
of Efficacy and Safety Outcomes] trials,25 although
the rate of AE-IPF was not a specific and separate
end point in this study.
Kubo and colleagues21 evaluated the effect of
anticoagulant therapy on the survival of patients
with IPF and found a beneficial effect on survival
of combined anticoagulant and prednisolone
therapy. This effect was largely driven by the
reduced incidence of AE-IPF in the warfarin group.
Few nonrandomized small studies investigated
the effect of polymyxin B–immobilized fiber
column (PMX) hemoperfusion treatment, showing
a potential beneficial effect of PMX treatment.
However, these results have largely been single-
center and need confirmation before affecting clin-
ical practice.49–51
Given the limited evidence, pharmacologic treat-
ment of AE-IPF is largely empiric and usually
consists of intravenous corticosteroids up to 1 g/d,
with or without immunosuppressive drugs. How-
ever, there are no controlled clinical trials to judge
the efficacy of this therapeutic strategy, and sub-
stantial difference of opinion between clinicians
exists regarding the appropriate treatment for
patients suffering from this complication. There-
fore, specific recommendations regarding dosage,
route, and duration of corticosteroid therapy
cannot be made at present.1 Nonpharmacologic
treatment of AE-IPF and progressive respiratory
failure in patients with IPF are discussed below.
NONPHARMACOLOGIC TREATMENTS
Despite the lack of high-quality data demonstrating
its benefit in patients with IPF, long-term oxygen
therapy is commonly prescribed to patients
showing resting hypoxemia or significant oxygen
desaturation on exercise, and is strongly recom-
mended by current guidelines.1 Due to the progres-
sive nature of IPF, higher flow rates than those
commonly used in chronic obstructive pulmonary
disease are likely to be required. Supplemental
oxygen may improve symptoms, quality of life,52
and endurance during rehabilitation training in
selected patients without exercise-induced hypox-
emia.53Conversely, long-termoxygen therapydoes
not affect survival.54 Supplemental oxygen therapy
is a critical component of the management of IPF,
and recentguidelines recommend its use inpatients
with clinically significant resting hypoxemia.1
Lack of energy and fatigue is a common and
disabling problem in IPF. Pulmonary rehabilitation
(PR), defined as a multidisciplinary intervention for
patients with chronic respiratory diseases who
are symptomatic and often have reduced activities
in daily life, is designed to alleviate symptoms and
optimize functional status by stabilizing and/or
reversing the extrapulmonary features of the
disease. Typical PR programs include exercise
training, nutritional modulation, occupational the-
rapy, education, and psychosocial counseling,
and consist of an initial intense component (usually
6–10 weeks) followed by a maintenance compo-
nent.55 At present, the most convincing evidence
of a beneficial effect of PR on quality of life and
functional mobility is derived from studies on
patients with pulmonary emphysema, although it
is conceivable that similar beneficial effects may
be achieved in patients with comparable disability
fromother chronic respiratory diseases.56 Previous
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studies, in which the physical training was com-
pared with no physical training or other therapy,
were not limited to patients with IPF, thus including
conditions potentially more amenable to the bene-
ficial effect of PR. In anRCTon the effect of 8weeks
of exercise-based PR in 57 patients with interstitial
lung diseases, including 34 patients with IPF,
Holland and colleagues57 observed that the
increase in 6MWD and the reduction in dyspnea
and fatigue among patients with IPF were not as
remarkable as among the non-IPF ones. In ad-
dition, these benefits were seen immediately
following training but were not sustained 6 months
after intervention. Patients with IPF tend with time
to discontinue any routine exercise because of
increasing dyspnea, which should be discouraged
whenever possible. Indeed, exercise such as daily
walks or the use of a stationary bicycle improves
muscle strength and increases the sense of well-
being.
The clinical course (progressive disease or
associated with acute exacerbation) of IPF is often
complicated by respiratory failure, and patients
may be referred to the intensive care unit to
receive ventilator support. However, mortality
during the hospitalization is high.58,59 In addition,
patients with end-stage interstitial lung disease
are difficult to ventilate and are rarely successfully
weaned from mechanical ventilation.58,60 Thus,
while the decision not to ventilate a patient with
IPF who also has acute respiratory failure is a tricky
one, mechanical ventilation should be introduced
only after carefully weighing up the patient’s
long-term prognosis and, whenever possible, the
patient’s wishes. The use of mechanical ventilation
is discouraged by current guidelines.1 Lung trans-
plantation might be regarded as the last thera-
peutic option for patients with acute respiratory
failure, in particular in younger patients with a firmly
established diagnosis. In these patients, mechan-
ical ventilation or extracorporeal life support
(extracorporeal membrane oxygenation) may be
used as a direct bridge to lung transplant.61
The outcome of life support as compared with
palliative care should be discussed with patients
and their families at an earlier stage. Palliative
care should start when patients with a progressive
disease become symptomatic, which means that
in some patients with IPF this type of intervention
should start as early as the diagnosis is estab-
lished. In IPF, dyspnea can be extremely distress-
ing, thus impairing physical activity and quality of
life. In selected cases of particularly severe dysp-
nea, morphine could be considered. In a small
case series, Allen and colleagues62 reported that
low-dose diamorphine reduces dyspnea, anxiety,
and cough without significant decrease in oxygen
saturation. Further, oxygen therapy may be useful
for palliation of dyspnea in hypoxemic patients.
With disease progression, patients may also
experience fear, anxiety, and depression; psycho-
logical counseling and, in selected cases, pharma-
cologic treatment should therefore be considered.
In a recent cross-sectional study of outpatients
with interstitial lungdisease, including IPF, Ryerson
and colleagues63 reported that dyspnea is strongly
associated with depression score, functional
status (as assessed by 4 minutes walk time), and
pulmonary function. These investigators demon-
strated that the relationship between dyspnea
and depression is independent of other clinical
variables, thus suggesting that treatment of
depression (observed in as many as 23% of
patients in this study) may improve dyspnea and
quality of life. The poor prognosis and significantly
impaired quality of life in patients with IPF make
palliative care an urgent need in these patients.
LUNG TRANSPLANTATION
Pulmonary fibrosis represents the second most
frequent disease for which lung transplantation is
performed.64 More recently the number of lung
transplants performed for IPF has steadily in-
creased, particularly in the United States, where
IPF now represents the leading indication for
lung transplantation.65 Five-year survival rates
after lung transplantation in IPF are estimated at
50% to 56%.62,66,67 Additional evidence suggests
that patients with pulmonary fibrosis undergoing
lung transplantation have favorable long-term
survival compared with other disease indications67
(see article elsewhere in this issue).
SUMMARY
Despite more than a decade of efforts to show
a definite effect on disease course in IPF, a treat-
ment regimen that is unanimously recognized as
a standard of care is still lacking. Current guidelines
recommend enrollment in clinical trials as the stan-
dard of care for patients with IPF. However, given
that one drug, pirfenidone, is currently approved
for the treatment of IPF in parts of the world that
are home to about 2 billion people, it is reasonable
to say that a major step forward has been made
with the identification of this drug. Nonetheless
there is no global recognition of this fact, and it is
fair to say that if pirfenidone can be seen as a start-
ing point in the treatment of IPF, it cannot be seen
as a point of arrival. Based on the current knowl-
edge of IPF pathogenesis, it is easy to predict
that the future treatment of IPF will be based on
multiple drugs. Although this is discouraging on
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one hand, on the other hand identification of more
milestone drugs is getting closer, and it seems
likely that within a few years the first globally
accepted standard of care will become a reality
for the management of this deadly disease. The
knowledge gained until now and the one that will
be gained over the next few years are important
and will also form the basis to approach the vast
and heterogeneous spectrum represented by the
other fibrotic interstitial lung diseases, for which
a systematic attempt to discover an effective phar-
macologic treatment is almost completely lacking.
In this way, patients with IPF will lead the way in the
discovery of therapies for lung fibrosis and, while
achieving the important critical goal of the identifi-
cation of the first effective treatment, will also help
the large number of patients with non-IPF fibrotic
lung disorders.
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